 | |
| Clinical data | |
|---|---|
| Routes of administration | S.C.[1] |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 100% (withS.C. administration)[1] |
| Eliminationhalf-life | 1.7 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C32H41N5O4 |
| Molar mass | 559.711 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
BMS-470539 is asmall-moleculeexperimental drug which acts as apotent and highlyselectivefull agonist of theMC1 receptor.[1][2] It was discovered in 2003 as part of an effort to understand the role of the MC1 receptor inimmunomodulation, and has since been used inscientific research to determine its role ininflammatory processes.[1][2][3] The compound wasdesigned with the intention ofmimicking the central His-Phe-Arg-Trppharmacophore of themelanocortins,[1][2] and this proved to be successful based on its favorablepharmacodynamic profile.
| pyrazolones / pyrazolidines | |
|---|---|
| salicylates | |
| acetic acid derivatives and related substances | |
| oxicams | |
| propionic acid derivatives (profens) |
|
| n-arylanthranilic acids (fenamates) | |
| COX-2 inhibitors (coxibs) | |
| other | |
| NSAID combinations | |
Key:underline indicates initially developed first-in-class compound of specific group;#WHO-Essential Medicines;†withdrawn drugs;‡veterinary use. | |
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |
